After the French drugmaker Sanofi India Limited recently discontinued ShanIPV, its inactivated polio vaccine (IPV), in India, the company has confirmed that it will ensure there is no interruption in the availability its IPV vaccine.
“We have already obtained the approvals for our product, IMOVAX-Polio, an alternative IPV that has been in use in more than 100 countries for 40-plus years. It also has the same composition/formulation as ShanIPV,” the company’s spokesperson said, following widespread concern that a pull out could lead to shortage of the vaccine in India.
Only recently, activists, public health experts, tuberculosis (TB) survivors, and people living with HIV had sought Prime Minister Narendra Modi’s intervention to halt what they said were frequent shortages in the availability of anti-TB drugs.
